Benign Conditions

The FDA has granted 510(k) clearance for American Medical Systems, Inc.’s RetroArc retropubic sling system for treatment of female stress urinary incontinence.

Ceftolozane/tazobactam, an investigational antibiotic, showed positive top-line results in a pivotal phase III clinical trial of the drug’s use in complicated urinary tract infections, Cubist Pharmaceuticals, Inc. reported.

The latest products and services from Mission Pharmacal, Eli Lilly, Richard Wolf Medical Instruments Corp., and Inspire on Purpose Publishing.

The use of voided midstream urine cultures in diagnosing cystitis has limited value but can be modified to avoid undertreatment and inappropriate treatment, according to a recently published study.

An investigational minimally invasive device was found safe and effective in limiting rapid pressure changes within the bladder to reduce symptoms of stress urinary incontinence, the authors of a recently published trial reported.

The FDA has approved a product label addition for the phosphodiesterase-type-5 inhibitor tadalafil (Cialis) that involves its use with finasteride (Proscar).

Urology drugs and devices in the pipeline from AltheRx Pharmaceuticals, TARIS Biomedical, AstraZeneca, NxThera, NovaBay Pharmaceuticals, and OncoGenex Pharmaceuticals.

The latest products and services from SuperSonic Imagine, Auxilium Pharmaceuticals, VIVUS, the Centers for Medicare & Medicaid Services, Innovus Pharmaceuticals, Buffalo Filter, KRS Global Biotechnology, Demos Health, and Ethicon Endo-Surgery.

Vitamin D does not appear to increase risk for developing kidney stones, say researchers from the University of California, San Diego.

Women with common forms of urinary incontinence have various bacteria in their bladder, according to a recent study, and some of these bacteria may differ based on their incontinence type.

Thulium vapoenucleation of the prostate provided significant and durable symptomatic improvement in benign prostatic obstruction, long-term follow-up of a clinical series showed.

In this article, I examine and question the phenomenon of “the urine drop-off”-having the patient with suspected UTI collect a urine sample at home and drop it off at the practice-in the context of best clinical practice, common sense, and basic office efficiency.

While women are far more likely to suffer from urinary tract infections, men are more likely to be hospitalized for treatment, according to a study by urologists from Henry Ford Hospital in Detroit.

The latest products and services from Cook Medical, American Medical Systems, Dialog Medical, Astellas Pharma U.S., Giffen Solutions, the Société Internationale d’Urologie, Merck Consumer Care, and the Bladder Cancer Advocacy Network.

In this interview, Brian R. Matlaga, MD, MPH, discusses factors to consider in the decision to utilize ureteroscopy versus shock wave lithotripsy, how to counsel patients on the optimal approach, how to minimize the morbidity of each modality, and why younger urologists are more likely to perform ureteroscopy.

The American Society for Radiation Oncology and the American Academy of Family Physicians have both released recommendations on the diagnosis and treatment of prostate cancer as part of the Choosing Wisely campaign.

A recent study has shown that in women with moderate-to-severe stress urinary incontinence, surgery is more effective than physiotherapy.

Following suburethral mesh sling removal, half of patients had operations to treat incontinence, according to a study reported at the AUA annual meeting in San Diego.

Three different procedures to treat stress urinary incontinence led to high rates of recurrence-free outcomes at 5 years, and the choice of retreatment of SUI varied according to the initial procedure, long-term follow-up in two randomized trials showed.

Need for a repeat voiding trial after midurethral sling surgery does not increase the likelihood of a suboptimal outcome and may even predict a better long-term result, say researchers from the Urinary Incontinence Treatment Network.

The FDA has authorized the marketing of the UroLift system, the first permanent implant to relieve low or blocked urine flow in men aged 50 years and older with BPH.

Houston-based Texas Children’s Hospital has opened a new pediatric stone clinic to provide comprehensive care for children and adolescents with kidney stones.

The risk of women developing kidney stones is rising, as is the number of cases being seen in U.S. emergency departments, while the rate of hospitalization for the disorder has remained stable, recent study findings indicate.

Total annual costs for major health care-associated infections (HAIs) were estimated at $9.8 billion in a recent study, with catheter-associated urinary tract infections representing

Most urologists agree that surgical removal of the enlarged portion of the prostate is the most effective and durable way to manage lower urinary tract symptoms in men secondary to BPH. Where it gets interesting is deriving urologic consensus on the best way to achieve that goal.

Could bacteria in the lower urinary tract play a role in urologic chronic pelvic pain syndrome (CPPS)? The jury is still out, but the authors of a new study say they weren’t able to find any evidence that germs are at fault.

A new study has found that testosterone replacement doesn’t worsen lower urinary tract symptoms related to an enlarged prostate. In fact, many men saw their symptoms improve, apparently with little effect on their prostate gland.

The latest products and services from neoSurgical, Wiley-Blackwell, iURO, and USARAD.com.

As follow-up lengthens in a prospective, randomized, controlled trial, men who underwent bipolar plasma vaporization of the prostate for BPH using the “button” vapo-resection electrode continue to demonstrate significantly better symptom scores and voiding characteristics compared to their counterparts treated by bipolar transurethral resection in saline or monopolar transurethral resection of the prostate.

In the treatment of BPH, while both bipolar-transurethral resection of the prostate (B-TURP) and monopolar-TURP (M-TURP) have similar clinical efficacy, B-TURP is associated with fewer adverse events, according to a recent systematic review of the two modalities.